Health
Mr. Kong, Nano Labs' Chairman and CEO, Increased His Shareholding in the Company
HANGZHOU, China , May 7, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, announced today that Mr. Jianping Kong, the Company's chairman and chief executive officer, inf...
2024-05-07 21:00
2337
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
2024-05-07 13:27
1329
Datasea Pre-Announces Estimated Revenue of $12.5 Million for April 2024 Supporting its Prior Revenue Guidance of $86 Million for Fiscal 2024
DTSS on Track to Achieve Record Revenue for Fiscal 2024 as it Further Penetrates China's$528 Billion 5G Market BEIJING, May 6, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada and engaged in innovative business seg...
2024-05-06 22:00
2273
German car manufacturer visits HoneyNaps, a South Korean sleep tech company, to develop new automotive healthcare applications
Monitoring biosignals for both drivers and passengers - Analyzing and diagnosing with FDA-approved algorithm SEOUL, South Korea, May 6, 2024 /PRNewswire/ -- Amid the rapid advancement in automobile healthcare and digital healthcare markets, global car manufacturers are racing to adopt cutting ed...
2024-05-06 22:00
1359
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...
2024-05-03 19:00
2291
Zepp Health's Amazfit Unveils Bip 5 Unity: Elevating Health and Style Every Step of the Way
MILPITAS, Calif., May 2, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp
Health") (NYSE:ZEPP
2024-05-02 23:00
2187
Boryung Launches 2024 Humans In Space Challenge: Sending Experiments into Orbit
* Boryung to support the launch of space experiments into orbit for selected startups and researchers * Held for the third consecutive year, HIS presents an expanded ecosystem of engagements with NASA, ISS National Lab,MIT, and major space companies * Humans In Space(HIS) will serve as a glo...
2024-05-02 20:00
1596
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...
2024-05-02 07:01
1710
Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry
BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...
2024-05-01 17:14
1316
135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management
GUANGZHOU, China, May 1, 2024 /PRNewswire/ -- In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from theMedicines, Health Products and Medical Devices secto...
2024-05-01 13:40
1454
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief ...
2024-05-01 08:59
1416
Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...
2024-04-30 23:00
2492
Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World
THE HAGUE, Netherlands, April 30, 2024 /PRNewswire/ -- The 12th Microbiome and Probiotics R&D and Business Collaboration Forum was held with great fanfare in The Hague, Netherlands from April 23rd to 24th, 2024. This prestigious conference is a leading event in the probiotics sector, drawing toget...
2024-04-30 21:09
1569
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...
2024-04-30 20:55
1515
A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs
NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...
2024-04-30 20:16
1533
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed...
2024-04-30 19:00
2849
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...
2024-04-30 19:00
1375
111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow
SHANGHAI, April 30, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial result...
2024-04-30 14:30
1452
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
* The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. * The Company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of Scope 1 and Scope 2 greenhouse gas ...
2024-04-30 10:55
1474
Waterdrop Inc. Releases 2023 Annual Report: Sustained Profitability and Impressive Growth in Innovative Businesses
BEIJING, April 29, 2024 /PRNewswire/ -- On April 25, 2024, Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, released its annual report on Form 20-F for the fiscal year ending...
2024-04-30 10:39
3021
Week's Top Stories
Most Reposted
ROSHI Unveils Comprehensive Report on the Future of Digital Lending, Highlighting Global Trends for 2025 and Beyond
[Picked up by 317 media titles]
2024-10-02 10:03
Matterport Fall 2024 Release: Insights Meets Imagination elevates the platform with generative AI and more
[Picked up by 305 media titles]
2024-10-02 09:00
From Boomers to Zoomers: how retailers and eCommerce firms can boost sales and loyalty
[Picked up by 305 media titles]
2024-09-30 13:00
Graid Technology and INFINITIX Turn Your SuperPOD into a Real Business Opportunity at Tech Week Singapore
[Picked up by 293 media titles]
2024-10-04 11:00
MOAJ Holding invests $30M in Joint Venture with MediSun Energy to Tackle Water Scarcity and Brine Challenges in Saudi Arabia
[Picked up by 293 media titles]
2024-09-30 09:00
Most Read
Matterport Fall 2024 Release: Insights Meets Imagination elevates the platform with generative AI and more
2024-10-02 09:00
8938
ROSHI Unveils Comprehensive Report on the Future of Digital Lending, Highlighting Global Trends for 2025 and Beyond
2024-10-02 10:03
8351
From Boomers to Zoomers: how retailers and eCommerce firms can boost sales and loyalty
2024-09-30 13:00
6938